PTC Therapeutics (PTCT) Q1 2026 earnings review
Sephience Rescues the Top Line as Legacy Products Fade
PTC Therapeutics delivered a pivotal Q1 2026, driven entirely by the explosive launch of Sephience. Net product revenue surged 47% YoY to $225.6M, allowing management to confidently raise FY26 product guidance. This growth masked a brutal reality in the legacy portfolio: Emflaza revenue collapsed 55% YoY due to generic competition. However, strict cost controls and $125M in Sephience sales brought Net Income to near-breakeven (-$2.8M), a massive stabilization compared to the heavy losses of late 2025. PTCT is now a single-asset commercial growth story, but the asset is delivering.
🐂 Bull Case
The PKU drug generated $124.6M in Q1, up 36% QoQ. With 1,244 active commercial patients and US start forms continuously clearing 140 per month, the $750-$850M FY26 product revenue guidance looks highly achievable.
Management held Non-GAAP OpEx remarkably stable at $163.6M (down slightly YoY), translating explosive top-line growth directly into bottom-line recovery. Cash burn is effectively neutralized with a $1.89B war chest.
🐻 Bear Case
Despite past claims of 'brand loyalty' against generic entrants, Emflaza sales collapsed from $47.8M in 25Q1 to $21.5M in 26Q1. The legacy floor is lower than anticipated.
The Vatiquinone program for Friedreich's ataxia hit a wall. FDA feedback mandates a brand new open-label registration study starting in Q3 2026, pushing potential commercialization out by years and accumulating R&D costs.
⚖️ Verdict: 🟢
Bullish. The speed at which Sephience is cannibalizing its market and absorbing the losses from Emflaza and Translarna validates the management's hyper-focus on this asset. The raise in full-year guidance confirms the momentum.
Key Themes
Sephience Launch Accelerating
Sephience continues its tear, recording $124.6M in 26Q1 (up 36% QoQ). The US accounted for $112M, while ex-US kicked in $13M. With the first commercial sales landing in Japan this quarter and a target of 30 countries by year-end, international rollout will take the baton as US growth normalizes.
Emflaza's Generic Cliff Contradicts Past Defenses
In early 2025, management claimed their 'white glove service' was successfully defending Emflaza against generic erosion. The data says otherwise: revenue decelerated rapidly, dropping 55% YoY to $21.5M. The legacy buffer is evaporating faster than projected, making Sephience's success absolutely mandatory.
Votoplam Proves Splicing Platform Value
Innovation is paying off. The 24-month PIVOT-HD study for Votoplam (an oral small molecule splicing agent) showed a 52% slowing of disease progression at the 10 mg dose with no treatment-related NfL spikes. This triggered a $50M Phase 3 milestone payment from Novartis, validating the technology and shifting the asset from pipeline promise to tangible cash.
Vatiquinone Sent Back to the Drawing Board
After months of regulatory limbo, the FDA demanded a new open-label registration study using a matched natural history control for Vatiquinone. While management spins this as 'FDA feedback,' it represents a severe delay. The study won't even initiate until Q3 2026, meaning zero revenue from this asset in the near-term.
Translarna Bounces on Temporary Brazil Order
Translarna revenue jumped to $59.0M in Q1, reversing a strict downward trend. However, management explicitly noted this was driven by a 'large government purchase order from Brazil.' This is a lumpy, non-recurring catalyst, and underlying ex-US demand continues to face headwinds following European regulatory withdrawals.
Macro: Ex-US Expansion Hinges on HTA Negotiations
Management wants Sephience in 30 countries by the end of 2026. However, the macroeconomic reality of rare disease pricing in Europe and LATAM means protracted Health Technology Assessment (HTA) negotiations. If these stall, the $13M ex-US revenue stream will fail to scale as projected.
Other KPIs
Stable. Non-GAAP R&D ($89.7M) and SG&A ($73.9M) combined for $163.6M, tracking well below the $171.8M spent in 25Q1. This discipline is exactly what investors want to see during an aggressive commercial launch—proving the company can scale revenue without bloated marketing spend.
Accelerating. Up 28% YoY from $36.4M in 25Q1, driven by Roche's global sales of 464M CHF. This high-margin cash stream provides an excellent financial cushion while the proprietary pipeline matures.
Guidance
Accelerating. Management raised the bottom of the previous range by $50M. At the $800M midpoint, it requires averaging ~$190M per quarter for the rest of the year. Given 26Q1 hit $225.6M (aided by a lumpy Translarna order), the guidance looks conservative and highly achievable.
Stable. The company maintained its OpEx guidance. At the midpoint ($700M), this implies ~$175M per quarter, slightly above the 26Q1 run rate of $163M, leaving room for Vatiquinone trial initiation costs in Q3.
Key Questions
Translarna's Base Rate
How much of the $59.0M Translarna revenue was strictly attributable to the Brazilian government order, and what is the true underlying run-rate ex-Brazil?
Emflaza Floor
With Emflaza dropping 55% YoY, do you see a floor for this product in 2026, or should investors model it trending toward zero by 2027?
Vatiquinone Costs
How much additional R&D spend is allocated for the new Vatiquinone open-label registration study, and does this alter your timeline for achieving sustained cash flow positivity?
Sephience Ex-US Margins
As Sephience expands to 30 countries by year-end, how should we think about the gross-to-net impact in these new geographies compared to the US?